Alpha 2.0
Login Register
» Authors » P Lagadec

P Lagadec

Explore the profile of P Lagadec including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 39
Citations 204
Followers 0
Related Specialties
Oncology
Allergy & Immunology
Pharmacology
Top 10 Co-Authors
J F Jeannin
D Reisser
H Pelletier
N Onier
F Martin
N O Olsson
C Fady
P Lejeune
V Imbert
J Bauer
Published In
Immunobiology
Cancer Immunol Immunother
Anticancer Res
C R Seances Soc Biol Fil
Leukemia
Affiliations
Soon will be listed here.
Recent Articles
1.
The response of pre-osteoblasts and osteoclasts to gallium containing mesoporous bioactive glasses
Gomez-Cerezo N, Verron E, Montouillout V, Fayon F, Lagadec P, Bouler J, et al.
Acta Biomater . 2018 Jul; 76:333-343. PMID: 29966758
Statement Of Signifcance: Osteoporosis is the most prevalent bone disease affecting millions of patients every year. However, there is a lack of bone grafts specifically designed for the treatment of...
2.
DOCK4 promotes loss of proliferation in glioblastoma progenitor cells through nuclear beta-catenin accumulation and subsequent miR-302-367 cluster expression
Debruyne D, Turchi L, Burel-Vandenbos F, Fareh M, Almairac F, Virolle V, et al.
Oncogene . 2017 Sep; 37(2):241-254. PMID: 28925399
Glioblastomas (GBM) are lethal primitive brain tumours characterized by a strong intra-tumour heterogeneity. We observed in GBM tissues the coexistence of functionally divergent micro-territories either enriched in more differentiated and...
3.
The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells
Mourgues L, Imbert V, Nebout M, Colosetti P, Neffati Z, Lagadec P, et al.
Leukemia . 2015 May; 29(10):1993-2002. PMID: 25925206
The BMI1 polycomb protein regulates self-renewal, proliferation and survival of cancer-initiating cells essentially through epigenetic repression of the CDKN2A tumor suppressor locus. We demonstrate here for the first time that...
4.
["There are three sorts of people: those who are alive, those who are dead, and those who are at sea" (Aristotle): reply]
Lagadec P
Ann Fr Anesth Reanim . 2014 Mar; 33(3):196-7. PMID: 24581868
No abstract available.
5.
[Explorers]
Lagadec P
Ann Fr Anesth Reanim . 2013 Aug; 32(9):541-3. PMID: 23948028
No abstract available.
6.
Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells
Lagadec P, Griessinger E, Nawrot M, Fenouille N, Colosetti P, Imbert V, et al.
Br J Cancer . 2008 Jan; 98(2):335-44. PMID: 18182997
NF-kappaB interferes with the effect of most anti-cancer drugs through induction of anti-apoptotic genes. Targeting NF-kappaB is therefore expected to potentiate conventional treatments in adjuvant strategies. Here we used a...
7.
Design of a digital phantom of the neonatal brain
Kazemi K, Grebe R, Moghaddam A, Lagadec P, Gondry-Jouet C, Wallois F
Annu Int Conf IEEE Eng Med Biol Soc . 2007 Nov; 2007:5509-12. PMID: 18003259
In this paper, we present the design and implementation of a 3D digital phantom of the neonatal brain. Commonly used digital brain phantoms (e.g. BrainWeb) are based on adults' brains....
8.
AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells
Griessinger E, Imbert V, Lagadec P, Gonthier N, Dubreuil P, Romanelli A, et al.
Leukemia . 2007 Mar; 21(5):877-85. PMID: 17330097
Acute myeloid leukemia (AML) cells carry molecular defects that promote their leukemic proliferation, resistance to apoptosis and defect in differentiation. Pharmacological targeting of the nuclear factor kappaB (NF-kappaB) pathway has...
9.
Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in tumor cells. Implications for tumor development
Lagadec P, Raynal S, Lieubeau B, Onier N, Arnould L, Lawrence D, et al.
Am J Pathol . 1999 Jun; 154(6):1867-76. PMID: 10362813
Transforming growth factor-beta1 (TGF-beta1) has been shown to down-regulate NO synthesis in a variety of normal cells. In the present study, we investigated the influence of TGF-beta1 upon NO production...
10.
Nitric oxide inhibits proliferation but increases life-span of T lymphocytes in tumour-bearing rats
Reisser D, Lagadec P, Arnould L, Onier N, Maupoil V, Pinard D, et al.
Cancer Immunol Immunother . 1998 Jun; 46(3):160-6. PMID: 9625539
Nitric oxide (NO) has been shown to inhibit the proliferation of lymphocytes. However, in tumour-bearing rats treated with the immunomodulator OM 163, the regressing nodules were heavily infiltrated by T...